We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 26, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sage Therapeutics, Inc. (SAGE - Free Report) , Biogen Inc. (BIIB - Free Report) , Agenus, Inc. (AGEN - Free Report) and BioMarin Pharmaceutical Inc. (BMRN - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Biotech Stock Update: Study Failures, Regulatory Updates & More
It was a low-key week for the biotech sector, with nothing important from the bigwigs. Regular pipeline and other updates continue to be in the news. Among these, Sage Therapeutics, Inc. is facing the brunt of investors due to the failure of a mid-stage study.
Recap of the Week's Most Important Stories:
SAGE Plummets on Study Failure: SAGE and partner Biogen Inc. announced the failure of a mid-stage study on oral investigational drug SAGE-324 (BIIB124) as a potential treatment in essential tremor (ET).
The phase II KINETIC 2 dose-range study did not demonstrate a statistically significant dose-response relationship in change from baseline to day 91 based on the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score in participants with ET.
Additionally, there was no statistically significant difference demonstrated for any dose of SAGE-324 as compared to placebo in the change from baseline to day 91 on the TETRAS PS Item 4 Total Score or the TETRAS Activities of Daily Living Composite Score.
Owing to the dismal results, SAGE and Biogen will close the ongoing open-label safety study of SAGE-324 in ET and do not plan to conduct any further clinical development of the same. Shares of SAGE plummeted on the news.
AGEN Tanks on Data: Agenus, Inc. announced the outcome of its end-of-phase II (EOP2) meeting with the FDA regarding the accelerated development of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL).
The BOT/BAL combination is being studied for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases.
The FDA discouraged the accelerated approval pathway for the BOT/BAL combination in r/r MSS CRC. As per the regulatory body, the objective response rate (ORR) observed in the phase II study might not convert to survival benefit.
AGEN announced top-line interim data from a phase II study that evaluated the BOT/BAL combination in r/r MSS CRC. The interim data demonstrated the best activity at 75 mg BOT/240mg BAL combination, which led to an ORR of 19.4%. Also, at the same dose, 90% of the patients were alive.
Per the press release, the company has reached an agreement with the FDA on the proposed dose of the BOT/BAL combination for a phase III study. The agreed dosing of the BOT/BAL combination regimen is BOT (75mg) once every six weeks for up to four doses, in combination with BAL (240mg), once every two weeks for up to two years.
The FDA has also proposed to include a BOT monotherapy arm in the phase III study. AGEN is currently looking for a partner in the United States to conduct the study.
BMRN's Drug Label Expansion: BioMarin Pharmaceutical Inc. announced that the FDA has approved the label expansion of Brineura. The drug is now approved to slow the loss of ambulation in children of all ages with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
The drug is already approved in symptomatic children, aged 3 years and older, with late infantile CLN2 disease. This expanded indication now includes children of all ages with CLN2 disease, regardless of whether they are symptomatic or presymptomatic.
The supplemental biologics license application is supported by data from the phase II study 190-203, evaluating Brineura treatment over the span of approximately three years in children aged 1-6 years at baseline, including eight children less than 3 years of age.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
For Immediate Release
Chicago, IL – July 26, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sage Therapeutics, Inc. (SAGE - Free Report) , Biogen Inc. (BIIB - Free Report) , Agenus, Inc. (AGEN - Free Report) and BioMarin Pharmaceutical Inc. (BMRN - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Biotech Stock Update: Study Failures, Regulatory Updates & More
It was a low-key week for the biotech sector, with nothing important from the bigwigs. Regular pipeline and other updates continue to be in the news. Among these, Sage Therapeutics, Inc. is facing the brunt of investors due to the failure of a mid-stage study.
Recap of the Week's Most Important Stories:
SAGE Plummets on Study Failure: SAGE and partner Biogen Inc. announced the failure of a mid-stage study on oral investigational drug SAGE-324 (BIIB124) as a potential treatment in essential tremor (ET).
The phase II KINETIC 2 dose-range study did not demonstrate a statistically significant dose-response relationship in change from baseline to day 91 based on the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score in participants with ET.
Additionally, there was no statistically significant difference demonstrated for any dose of SAGE-324 as compared to placebo in the change from baseline to day 91 on the TETRAS PS Item 4 Total Score or the TETRAS Activities of Daily Living Composite Score.
Owing to the dismal results, SAGE and Biogen will close the ongoing open-label safety study of SAGE-324 in ET and do not plan to conduct any further clinical development of the same. Shares of SAGE plummeted on the news.
AGEN Tanks on Data: Agenus, Inc. announced the outcome of its end-of-phase II (EOP2) meeting with the FDA regarding the accelerated development of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL).
The BOT/BAL combination is being studied for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases.
The FDA discouraged the accelerated approval pathway for the BOT/BAL combination in r/r MSS CRC. As per the regulatory body, the objective response rate (ORR) observed in the phase II study might not convert to survival benefit.
AGEN announced top-line interim data from a phase II study that evaluated the BOT/BAL combination in r/r MSS CRC. The interim data demonstrated the best activity at 75 mg BOT/240mg BAL combination, which led to an ORR of 19.4%. Also, at the same dose, 90% of the patients were alive.
Per the press release, the company has reached an agreement with the FDA on the proposed dose of the BOT/BAL combination for a phase III study. The agreed dosing of the BOT/BAL combination regimen is BOT (75mg) once every six weeks for up to four doses, in combination with BAL (240mg), once every two weeks for up to two years.
The FDA has also proposed to include a BOT monotherapy arm in the phase III study. AGEN is currently looking for a partner in the United States to conduct the study.
BMRN's Drug Label Expansion: BioMarin Pharmaceutical Inc. announced that the FDA has approved the label expansion of Brineura. The drug is now approved to slow the loss of ambulation in children of all ages with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
The drug is already approved in symptomatic children, aged 3 years and older, with late infantile CLN2 disease. This expanded indication now includes children of all ages with CLN2 disease, regardless of whether they are symptomatic or presymptomatic.
The supplemental biologics license application is supported by data from the phase II study 190-203, evaluating Brineura treatment over the span of approximately three years in children aged 1-6 years at baseline, including eight children less than 3 years of age.
BMRN currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Performance
The Nasdaq Biotechnology Index has lost 0.75% in the past five trading sessions and BMY's shares have risen 3.50%. In the past six months, shares of MRNA have rallied 16.89%. (See the last biotech stock roundup here: Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.